Zobrazeno 1 - 10
of 67
pro vyhledávání: '"E. V. Titaeva"'
Autor:
M. B. Khakimova, A. L. Komarov, A. B. Dobrovolsky, E. V. Titaeva, V. V. Kadochnikova, D. D. Abramov, E. P. Panchenko
Publikováno v:
Атеротромбоз, Vol 13, Iss 2, Pp 16-27 (2024)
Introduction. Patients undergoing elective myocardial revascularization require 6 months of dual antiplatelet therapy (DAPT), including aspirin and clopidogrel. In patients with multifocal atherosclerotic lesion (MFA), it may be reasonable to extend
Externí odkaz:
https://doaj.org/article/4032d57357514dc6b0b82b1140824a58
Publikováno v:
Атеротромбоз, Vol 13, Iss 1, Pp 46-57 (2023)
Introduction. Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired liver function, extremely low or high body mass, chronic heart failure (CHF), and age > 90
Externí odkaz:
https://doaj.org/article/03e97d69c95149df81b09922849727b6
Autor:
Yu. A. Fedotkina, A. L. Komarov, А. В. Dobrovolsky, E. N. Krivosheeva, О. О. Frolkova, E. V. Titaeva, T. V. Balakhonova, Е. Р. Panchenko
Publikováno v:
Атеротромбоз, Vol 12, Iss 2, Pp 64-78 (2023)
Introduction. Thrombotic complications (TC) in different vascular systems dictate the fate of high-risk patients. In cardiological practice, patients with advanced atherosclerotic vascular disease (MFA) represent the most vulnerable group. Malignant
Externí odkaz:
https://doaj.org/article/2a42b5c63e7743ab8b51a593d268037a
Publikováno v:
Атеротромбоз, Vol 12, Iss 1, Pp 127-137 (2022)
Introduction. Increased expression of tissue factor by tumor cells, formation of procoagulant microparticles and secretion of proinflammatory cytokines that activate leukocytes and endothelial cells are considered to be the main factors provoking blo
Externí odkaz:
https://doaj.org/article/5e393ba21d134b9592ac17ee39c84e89
Publikováno v:
Атеротромбоз, Vol 12, Iss 1, Pp 20-28 (2022)
Currently, direct oral anticoagulants (DOACs) should be preferred when prescribing anticoagulant therapy to atrial fibrillation patients because of their lower potential for interactions and risk of bleeding than warfarin. However, in the absence of
Externí odkaz:
https://doaj.org/article/71611dab20b84396b106049e7821be96
Autor:
E. V. Titaeva, A. B. Dobrovolsky
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 96-104 (2020)
Introduction. The direct oral anticoagulants (DOC) therapy does not require alaboratory control; however, it may be required to determine the anticoagulationlevel to choose a treatment strategy if alarge bleeding is developing or emergency surgery is
Externí odkaz:
https://doaj.org/article/2dfb05b15f914b989b5b9a8f7b44b6f0
Autor:
O. O. Shakhmatova, A. L. Komarov, V. V. Korobkova, E. V. Titaeva, A. B. Dobrovolskiy, E. B. Yarovaya, A. G. Shuleshova, E. P. Panchenko
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 20, Iss 7 (2021)
Aim. To study the role of von Willebrand factor (VWF) and D-dimer (DD) as predictors of upper gastrointestinal bleeding (GIB) in patients with stable coronary artery disease (CAD).Material and methods. The study included patients with stable CAD who
Externí odkaz:
https://doaj.org/article/8aed6b76500049a496cd8219803d8124
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 7 (2021)
Aim. To study the predictive value of growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation (AF) after elective percutaneous coronary intervention (PCI).Material and methods. The study included 150 patients (men, 69,3%) with
Externí odkaz:
https://doaj.org/article/ba9a03d5455540a09be2d243a3e156c7
Autor:
A. I. Loginova, E. S. Kropacheva, E. V. Titaeva, E. B. Maykov, T. V. Balakhonova, S. P. Golitsyn
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 47, Iss 4, Pp 326-333 (2019)
Rationale: Thrombosis of the puncture site in the femoral veins is one of the potentially dangerous complications of intracardial catheter interventions associated with thromboembolic risk related to its proximal location. According to the literature
Externí odkaz:
https://doaj.org/article/f69cbfd910a34fef88658d22d1ea0c99
Autor:
E. V. Titaeva, A. B. Dobrovolsky
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 107-114 (2015)
Despite the development of new oral anticoagulants, vitamin K antagonists (VKA) continue to be widely used for the treatment and prevention of throm-boembolic complications. On top of that, they have no alternative in patients with artificial heart v
Externí odkaz:
https://doaj.org/article/cd36ab0324f34cf890b3dc0ef49644fc